RxDoctor Payments Data

Mitzi Thompson, NP

Women's Health · Spanish Fort, ALNPI 1891004834

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Novo Nordisk at 29.9% of the total. Among women's health clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,979in general payments, 2019–2025

Across 166 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$891
  • AbbVie$502
  • Lilly USA, LLC$299
  • Exact Sciences$293
  • Therapeuticsmd, Inc.$162
  • AstraZeneca$139
  • plus $693 from 21 others

What the payments were for

  • Food & beverage$2,979100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,979 in reported general payments places this provider in the 90th percentile of 107 women's health providers in Alabama.

See all women's health providers in Alabama

Medicare billing

Part B allowed, 2024
$10,886
Medicare patients
68
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$13,556
ProgesteroneProgesterone, Micronized67$4,056
Estradiol (Twice Weekly)Estradiol20$2,712
Estradiol22$2,011
Omeprazole13$333
Losartan Potassium14$242
Levothyroxine Sodium29$231
Metformin Hcl37$202
Rosuvastatin Calcium15$201
Escitalopram Oxalate14$112
Pantoprazole Sodium19$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$891$13,55614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 107 women's health providers in Alabama.

Other women's health in Spanish Fort

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →